One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.

@article{Amiot2017OneyearEA,
  title={One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.},
  author={Aur{\'e}lien Amiot and M{\'e}lanie Serrero and Laurent Peyrin-Biroulet and J{\'e}r{\^o}me Filippi and Benjamin Pariente and X Roblin and Anthony Buisson and Carmen Stefanescu and Caroline Trang-Poisson and Romain Altwegg and Philippe Marteau and Thibaud Vaysse and Anne Bourrier and St{\'e}phane Nancey and David Laharie and Matthieu Allez and Guillaume Savoye and Jacques Moreau and L Vuitton and St{\'e}phanie Viennot and Alexandre Aubourg and Andr{\'e}e Ann Pelletier and Guillaume Bouguen and Vered Abitbol and Charlotte Gagni{\`e}re and Yoram Bouhnik},
  journal={Alimentary pharmacology & therapeutics},
  year={2017},
  volume={46 3},
  pages={310-321}
}
BACKGROUND We recently showed that vedolizumab is effective in patients with Crohn's disease (CD) and ulcerative colitis (UC) with prior anti-TNF failure in a multicentre compassionate early-access programme before marketing authorisation was granted to vedolizumab. AIMS To assess effectiveness and safety of vedolizumab at week 54 in patients UC and CD. METHODS Between June and December 2014, 173 patients with Crohn's disease (CD) and 121 with ulcerative colitis (UC) were treated with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 11 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…